Barclays Raises Biogen Price Target to $230 From $200
Barclays maintained its Equal-Weight rating on Biogen, according to Benzinga.
Related stories
Takeda Pharmaceutical Company’s Q2 2027 earnings call begins
Takeda Pharmaceutical Company’s quarterly earnings call has begun.
M impact | EQUITY | Oct 29, 2026, 09:57 AM UTC
Montage Tech Q3 Net Profit Rises 161.98% Year Over Year
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Axis Real Estate Investment Trust Reports Q3 2026 Revenue of 90.8 Million RGT
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Axis Real Estate Investment Trust Reports Q3 2026 Profit of 54.8 Million RGT
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Haitian Flavoring's Q3 net profit falls more than a tenth
Haitian Flavoring reported third-quarter revenue of 64.1 hundred-million yuan, nearly flat year over year. The headline says net profit fell by more than a tenth.
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC
Axis REIT Reports Third-Quarter 2026 Results
Axis REIT reported revenue of MYR 90,779,000 and pretax profit of MYR 54,798,000 for the quarter ended September 30, 2026. Revenue was MYR 92,767,000 and pretax profit was MYR 52,1
M impact | EQUITY | Oct 29, 2026, 09:56 AM UTC